Prof. Shiloh is the 43rd Israeli researcher elected to the US National Academy, alongside Nobel brides and grooms such as Prof. Ada Yonat, Prof. Dan Shechtman and Prof. Aharon Chachanover
An achievement for Professor Emeritus Yossi Shilo From the Sackler Faculty of Medicine, who was elected a member of the US National Academy of Sciences (NAS). Today, the Academy has about 2,500 American scientists and another 500 scientists who are not US citizens from all fields of science and from all over the world. The acceptance threshold for non-American members is particularly high, so the appreciation towards the "international" members is high.
"This is a body whose opinion is heard and considered, and I hope that the opinion of the Israeli National Academy of Sciences, of which I am a member, will be heard here in a similar way."
Prof. Sheila received the exciting news while attending a conference in Boston. In the past he won the A.M.T. And the Israel Prize, and even the Clouse Prize - the most important prize awarded by the American Association for Cancer Research, which has thousands of cancer researchers as members. But this time it is a more widespread recognition, by all the members of the Academy, who come from a variety of scientific fields.
The National Academy of Sciences of the USA advises the American government and the nation in matters of science, engineering and medicine, and this by virtue of a bill of rights granted to it by Congress in 1863, which was signed by President Abraham Lincoln. Membership in the Academy is for life, with up to 120 new scientists from the USA and up to 30 foreign scientists from around the world being selected each year.
"This is a great honor and I thank the Academy for the exciting choice. This is a body whose opinion is heard and considered and I hope that the opinion of the Israeli National Academy of Sciences, of which I am a member, will be heard here in a similar way. In the US, the president, the administration and the public give their opinion on the matter of the academy, hence the weight that Americans attribute to membership in this institution", says Prof. Sheila. In a year he will participate in a ceremony in honor of the members chosen this year, which will be held at the Academy House in Washington, DC.
Research that has far-reaching effects on the fields of DNA repair and cancer research
"This is a huge honor for us at the school and the Faculty of Medicine at Tel Aviv University. Prof. Shiloh's research made a founding and amazing contribution to the study of the hereditary disease ataxia-telangiectasia (AT), a rare but devastating genetic disease. Prof. Sheila's research has far-reaching implications for the fields of DNA repair and cancer research. The most significant and fascinating thing is Prof. Shiloh's compassion for the patients, and his desire to reach new insights that will enable the improvement of patient care, which motivated him at every stage of his work on the disease, since he was a research student," says Prof. Keren Avraham, dean of the Faculty of Medicine, adding, "The main His work can be summed up in the title of the lecture he delivered to many audiences over the years: 'Researching rare genetic diseases: a mission for human well-being and a milestone in understanding our biology'. Prof. Sheila continues to research the key aspects of the AT disease - neurodegeneration and accelerated aging, using a variety of biological methods, and continues to devote efforts to educating the public regarding the medical and social consequences of the genome research revolution."
Prof. Yossi Shila is in charge of the David and Inez Meyers Chair for Cancer Genetics Research in the Department of Human Molecular Genetics and Biochemistry in the Faculty of Medicine of Tel Aviv University.
More of the topic in Hayadan:
- Prof. Yossi Shilo from Tel Aviv University won the prestigious award of the American Association for Cancer Research
- Compugen establishes Kedem Biosciences, a subsidiary for the discovery of small molecules for pharmaceutical purposes
- Researchers at Tel Aviv University have identified a protein that may serve as a new indicator of the grade of cancerous tumors
